SCHEMBL5540995

SCHEMBL5540995

CCOC(=O)CC(=O)N(CCN1CCCS1(O)O)c1cc(Cc2ccc(F)cc2)cnc1C(=O)OCC

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE3B Q13370 1/20 0.35
PDE3A Q14432 1/20 0.35
P2RY12 Q9H244 1/20 0.33
MAOB P27338 1/20 0.32
OPRM1 P35372 3/20 0.32
GABRG2 P18507 2/20 0.32
GABRB3 P28472 2/20 0.32
GABRA5 P31644 2/20 0.32
GABRA2 P47869 2/20 0.32
GABRB2 P47870 2/20 0.32
KMT2A Q03164 2/20 0.32
ATM Q13315 1/20 0.31
JMJD6 Q6NYC1 1/20 0.31
TLR2 O60603 1/20 0.31
MEN1 O00255 1/20 0.31
GABRP O00591 1/20 0.31
GABRD O14764 1/20 0.31
ALDH1A1 P00352 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP2D6 P10635 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5541256 0.98 PDE3B (0.34) PDE3BPDE3AP2RY12MAOBOPRM1
SCHEMBL5540997 0.93 PDE3B (0.35) PDE3BPDE3AP2RY12MAOBGABRG2
SCHEMBL6061219 0.92 MAOB (0.32) PDE3BPDE3AP2RY12MAOBOPRM1
SCHEMBL5541250 0.91 GRM2 (0.35) PDE3BPDE3AP2RY12MAOBGABRG2
SCHEMBL6061215 0.85 GRM2 (0.35) PDE3BPDE3AP2RY12MAOBOPRM1
SCHEMBL5545354 0.84 EPHX2 (0.42) PDE3BPDE3AP2RY12KMT2AMEN1
SCHEMBL5538668 0.81 PDE3B (0.40) PDE3BPDE3AALDH1A1TSHRCYP2C19
SCHEMBL5538835 0.81 PDE3B (0.38) PDE3BPDE3AKMT2AMEN1ALDH1A1
SCHEMBL5538851 0.81 PDE3B (0.38) PDE3BPDE3AKMT2AMEN1ALDH1A1
SCHEMBL5540813 0.81 PDE3B (0.38) PDE3BPDE3AP2RY12GABRG2GABRB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150225399-A1 HIV INTEGRASE INHIBITORS VIIV HEALTHCARE CO (US) 2015-08-13 US disclosed
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS SHIONOGI & CO., LTD. (JP) 2014-09-11 US disclosed
EP-1720856-B1 HIV INTEGRASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-08-14 EP disclosed
US-20070124152-A1 Hiv Integrase Inhibitors GLAXOSMITHKLINE LLC 2007-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS BCDIN3D, DUT, SAMHD1 PDE3B 3560/4885PDE3A 3339/4885P2RY12 3710/4885
US-20150225399-A1 HIV INTEGRASE INHIBITORS ING2, API5, SAMHD1 PDE3B 3316/4885PDE3A 3100/4885P2RY12 4326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.